+91 80 2808 2808
Biocon  /  Investor Relations  /  Stock Exchange Disclosures  /  Press Release


29-AprBiocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68% Net Profit (before exceptional item & discontinuing operations) at Rs 257 Cr; Biosimilars Up 53% at Rs 664Cr; Research Services Up 8% at Rs 659 Cr; Generics Up 3% at Rs 578 Cr. FY21 Revenue Up 14% at Rs 7,360 Cr; EBITDA Up 8% at Rs 1,907 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 754 Cr.
28-AprBiocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
28-AprCompany Statement: Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.
26-AprCompany Statement: Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
12-AprCompany Statement: Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, receives GMP compliance certificate from MHRA, UK
29-MarBiocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
02-MarBiocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
01-MarBiocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
01-MarBiocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
16-FebBiocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
12-FebCompany Statement: Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart
04-FebBiocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries, Will enable access to Trastuzumab & Pegfilgrastim in Africa & Asia
21-JanBiocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
21-JanProfessor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
07-JanBiocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
28-DecBiocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
25-DecCompany Statement: Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020
15-DecBiocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
14-DecCompany Statement: Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
07-NovBiocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs, Transaction Values Biocon Biologics at USD 3.94 Billion
30-OctBiocon Ranked Among Top 5 Biotech Employers Globally
22-OctPress Release on financial results for the Quarter ended September 30, 2020
08-OctBiocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
22-SepBiocon appoints Anupam Jindal as its Chief Financial Officer
31-AugBiocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
14-AugDisclosure of material impact of COVID 19 pandemic on the Company
03-AugExecution of SHA and SSA with Tata Capital Growth Fund II – Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015
31-JulTata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion
23-JulPress Release on financial results for the quarter ended June 30, 2020.
21-JulBiocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
11-JulBiocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
22-JunBiocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
12-JunBiocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
05-JunKiran Mazumdar-Shaw wins EY World Entrepreneur of the Year™ 2020 Award. She is the first woman entrepreneur from India and third Indian to win this title in WEOY Award’s 20-year History
01-JunBiocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
27-MayBiocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients
19-MayBiocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab
14-MayBiocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
12-MayCompany Statement: Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification
08-MayCompany Statement: Biocon’s Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection
28-AprBiocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada.
16-AprCompany Statement : Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed
14-AprBiocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
01-AprBiocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed

FY: From April 1 – March 31

Previous Next
Test Caption
Test Description goes like this